RAPT Therapeutics (RAPT) announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company’s lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E , a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year. Braunstein has been an operating partner at Aisling Capital since 2015. Dombkowski is currently CEO and President of Cellics Therapeutics, a biotechnology company developing novel biologics to address significant unmet medical needs in inflammation and immunology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.